Lv32
280 积分 2024-11-01 加入
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
18小时前
已完结
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA
12天前
已完结
PD-L1 induces autophagy and primary resistance to EGFR–TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway
12天前
已完结
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study
13天前
已完结
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
1个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
1个月前
已完结
Effect of early versus late or no tracheostomy on mortality and pneumonia of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis
1个月前
已完结
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
1个月前
已完结
Renal dysfunction during osimertinib treatment in patients with non–small cell lung cancer positive for EGFR mutations
1个月前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
